Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CJ-40002 in Healthy Male Volunteers
NCT02146625Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Nov 2014
- Primary completion
- Mar 2015
- Modality
- Drug Delivery Systems, Fc-Fusion Proteins
01
Overview
Phase 1, randomised, single-blind trial of ALT-P1 in growth hormone deficiency (GHD) (5 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Curve at 15 days, Maximum Concentration at 15 days and 1 more. Started Nov 2014; status: completed.
02
Drugs
ALT-P1
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02146625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146625.